1.520USD+2.70%Mkt Cap: 11.46M USDP/E: —Last update: 2026-05-22
BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that i…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap11.46M USD
Enterprise Value-1.64M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-17.54M USD
Revenue/Share—
Last Price1.520 USD
Fiscal Year EndJun 2025
MR QuarterMar 2026
Employees13
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.34
PEG—
EV/EBITDA0.08
EV/Revenue—
P/S—
P/B0.72
EPS (TTM)-3.79
EPS (Forward)-4.41
52W Range
1.0604% of range12.10
52W High12.10 USD
52W Low1.060 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-92.27%
ROA-81.36%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.03M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-124.38%
Net Debt-12.80M USD
Net Debt/EBITDA0.63
Balance Sheet
Debt/Equity0.02
Current Ratio9.97
Quick Ratio9.02
Book Value/Sh2.069 USD
Cash/Share1.737 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateNov 22, 2019
Splits
Last Split1:10
Split DateJul 7, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.7.54M
Float7.50M
Insiders0.36%
Institutions13.94%
Short Interest
Short Ratio2.5d
Short % Float2.36%
Short % Out.2.35%
Shares Short177.09K
Short (prev mo.)154.21K
Technical
SMA 501.447 (+5.1%)
SMA 2001.527 (-0.5%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)91.79K
Avg Vol (10d)80.18K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—